EMMPRIN and survivin: prognostic factors in cisplatin-treated patients with bladder cancer

被引：0
|
作者：
机构：
来源：
Nature Clinical Practice Oncology | 2007年 / 4卷 / 12期
关键词：
D O I：
10.1038/ncponc0938
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：676 / 676
相关论文
共 50 条
  • [41] IMMUNOCHEMICAL DETERMINATION OF PT-DNA ADDUCTS IN BLOOD-CELLS OF CISPLATIN-TREATED CANCER-PATIENTS
    FICHTINGERSCHEPMAN, AMJ
    VANOOSTEROM, AT
    LOHMAN, PHM
    MUTATION RESEARCH, 1987, 181 (02): : 344 - 344
  • [42] Detection of morphological changes in cisplatin-treated ovarian cancer cells by digital holographic microscopy
    Zhikhoreva, A. A.
    Belashov, A. V.
    Bespalov, V. G.
    Romanov, V. A.
    Semenov, A. L.
    Zhilinskaya, N. T.
    Semenova, I. V.
    Vasyutinskii, O. S.
    2018 INTERNATIONAL CONFERENCE LASER OPTICS (ICLO 2018), 2018, : 577 - 577
  • [43] Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: Multivariate analysis on prognostic factors
    Angulo, JC
    SanchezChapado, M
    Lopez, JI
    Flores, N
    JOURNAL OF UROLOGY, 1996, 155 (06): : 1897 - 1902
  • [44] FACTORS OF PROGNOSTIC AND THERAPEUTIC SIGNIFICANCE IN PATIENTS WITH BLADDER-CANCER
    BATATA, MA
    CHU, FCH
    HILARIS, BS
    KIM, YS
    LEE, MZ
    CHUNG, S
    WHITMORE, WF
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1981, 7 (05): : 575 - 579
  • [45] CISPLATIN-DNA INTERACTION PRODUCTS IN SENSITIVE AND RESISTANT CELL-LINES AND IN BUCCAL CELLS FROM CISPLATIN-TREATED CANCER-PATIENTS
    ENGELSE, LD
    TERHEGGEN, PMAB
    BEGG, AC
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 339 - 339
  • [46] Role of miR-21, miR372, and E2F1 as biomarkers predicting outcome in cisplatin-treated bladder cancer patients.
    Zhou, Chensheng Willa
    Mullane, Stephanie A.
    Werner, Lillian
    Taplin, Mary-Ellen
    Fay, Andre Poisl
    Choueiri, Toni K.
    Takeda, David Yoshio
    Bowden, Michaela
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] COMPARISON OF 3 PROTRACTED ANTIEMETIC REGIMENS FOR THE CONTROL OF DELAYED EMESIS IN CISPLATIN-TREATED PATIENTS
    MORENO, I
    ROSELL, R
    ABAD, A
    BARNADAS, A
    CARLES, J
    RIBELLES, N
    SOLANO, V
    FONT, A
    EUROPEAN JOURNAL OF CANCER, 1992, 28A (8-9) : 1344 - 1347
  • [48] Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin
    You, Min Su
    Ryu, Ji Kon
    Choi, Young Hoon
    Choi, Jin Ho
    Huh, Gunn
    Paik, Woo Hyun
    Lee, Sang Hyub
    Kim, Yong-Tae
    BMC CANCER, 2019, 19 (1)
  • [49] Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin
    Min su You
    Ji Kon Ryu
    Young Hoon Choi
    Jin Ho Choi
    Gunn Huh
    Woo Hyun Paik
    Sang Hyub Lee
    Yong-Tae Kim
    BMC Cancer, 19
  • [50] THERAPEUTIC OUTCOMES AND PROGNOSTIC FACTORS IN UNRESECTABLE GALLBLADDER CANCER TREATED WITH GEMCITABINE PLUS CISPLATIN
    You, Min Su
    Ryu, Ji Kon
    Choi, Young Hoon
    Shin, Bang-sup
    Paik, Woo Hyun
    Lee, Sang Hyub
    Kim, Yong-Tae
    GASTROENTEROLOGY, 2018, 154 (06) : S953 - S953
12345